首页> 外文期刊>Journal of refractive surgery >Wavefront-guided enhancements using the wavelight excimer laser in symptomatic eyes previously treated with LASIK.
【24h】

Wavefront-guided enhancements using the wavelight excimer laser in symptomatic eyes previously treated with LASIK.

机译:在先前用LASIK治疗的有症状眼睛中,使用波光准分子激光进行波前引导增强。

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

PURPOSE: To describe our clinical experience in wavefront-guided LASIK enhancements using the WaveLight ALLEGRETTO system (WaveLight Technologie AG, Erlangen, Germany) for symptomatic eyes previously treated with standard LASIK. METHODS: Twenty-six eyes of 20 patients with residual myopia, hyperopia, or mixed astigmatism and/or night vision symptoms after primary standard LASIK were considered for wavefront-guided customized retreatment using the WaveLight ALLEGRETTO WAVE 200 Hz excimer laser system (model 106). Preoperative best spectacle-corrected visual acuity (BSCVA), uncorrected visual acuity, topography with the ALLEGRETTO Topolyzer, wavefront analysis using the ALLEGRETTO WAVE Tscherning Analyzer, and contrast sensitivity were compared to postoperative (enhancement) measurements. RESULTS: Twenty-two of the original 26 eyes underwent wavefront-guided enhancement, 4 were excluded because they did not meet wavefront-guided treatment inclusion guidelines of this study. Mean follow-up was 8 months (range: 6 to 13 months, standard deviation [SD] 2). All patients were within +/- 0.50 diopters (manifest refraction) of intended postoperative refraction. The mean preoperative BSCVA improved from 20/25 (SD +/- 0.12) to 20/18 (SD +/- 0.1) postoperatively. All patients gained at least one line of BSCVA, and a maximum of three lines. There was no loss of BSCVA in any patient. The total amount of high order aberrations (RMSH) decreased from an average of 1.04 (SD +/- 0.22) to 0.46 (SD +/- 0.14) microm. Patients also had a mean improvement in low contrast sensitivity of 59%. CONCLUSIONS: Based on this small series, customized wavefront-guided enhancements using the WaveLight ALLEGRETTO system in patients who underwent previous LASIK appear to be safe and effective in correcting residual refractive error, reducing high order aberrations, and improving visual symptoms when reliable and reproducible measurements are achieved.
机译:目的:描述我们使用WaveLight ALLEGRETTO系统(WaveLight Technologie AG,德国埃尔兰根)在波前引导性LASIK增强术中的临床经验,该系统用于以前用标准LASIK治疗的症状性眼睛。方法:考虑将20例原发于标准LASIK术后残留近视,远视或混合散光和/或夜视症状的患者的26眼用于使用WaveLight ALLEGRETTO WAVE 200 Hz准分子激光系统进行波阵面引导的定制再治疗(106型) 。将术前最佳眼镜矫正视力(BSCVA),未矫正视力,使用ALLEGRETTO Topolyzer进行地形检查,使用ALLEGRETTO WAVE Tscherning Analyzer进行波前分析以及对比灵敏度与术后(增强)测量值进行比较。结果:最初的26只眼中有22只接受了波阵面引导的增强,因此排除了4只,因为它们不符合本研究的波阵面引导的治疗纳入指南。平均随访时间为8个月(范围:6到13个月,标准差[SD] 2)。所有患者均在术后预期屈光度的+/- 0.50屈光度之内。术前平均BSCVA从术后20/25(SD +/- 0.12)改善至20/18(SD +/- 0.1)。所有患者至少获得了一条BSCVA系,最多获得了3条系。任何患者均无BSCVA丢失。高阶像差(RMSH)的总量从平均值的1.04(SD +/- 0.22)降低到0.46(SD +/- 0.14)微米。患者的低对比敏感度平均改善了59%。结论:基于这一小系列研究,使用WaveLight ALLEGRETTO系统对接受过LASIK手术的患者进行定制的波前引导增强治疗,在可靠且可重复的测量结果中,对于校正残余屈光不正,减少高阶像差并改善视觉症状似乎是安全有效的。实现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号